Mount Tam Biotechnologies, Inc. announced that Dr. Jim Stolzenbach has been appointed as a scientific advisor to Mount Tam, bringing his expertise in drug development to support the advancement of its novel rapamycin analogs to address serious unmet need across a range of autoimmune and rare diseases. Jim Stolzenbach Ph.D. has extensive research and development experience in the pharmaceutical industry where currently he is President of Jim Stolzenbach Consulting, LLC.